Engineered immune cells take on tough lung cancer
NCT ID NCT07564401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard treatments. The goal is to find the right dose and check if the therapy is safe and shows signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DJI136 (a DLL3-targeted CAR-T cell therapy)
What this could lead to
If successful, this could offer a new treatment option for people with advanced small cell lung cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial (Phase I/II) with only 80 participants, so safety and effectiveness are not yet proven. CAR-T therapies can cause severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGSingapore, 168583, Singapore
-
University of Kentucky
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact